PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?

Volume: 29, Issue: 6, Pages: 960 - 969
Published: Feb 1, 2022
Abstract
Initially described as a factor involved in liver regeneration and neuronal differentiation, proprotein convertase subtilisin/kexin type 9 (PCSK9) has become one of the key regulators of low-density lipoprotein cholesterol. Beside that, a number of studies have suggested PCSK9 may play a role in cancer biology. This is particularly true for gastroenteric (gastric and liver cancers) and lung cancers, where higher PCSK9 levels were associated with...
Paper Details
Title
PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?
Published Date
Feb 1, 2022
Volume
29
Issue
6
Pages
960 - 969
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.